There was no excitement two days ago.
The eight-point newsletter was informed that this negotiation is a competitive negotiation and does not guarantee the access rate. That is to say, some of the 150 drugs involved in the negotiations may be out.
After three days, the pharmaceutical companies negotiated with each other, and some people were happy. The two drug companies that had successfully negotiated the negotiations were very excited. A pharmaceutical company that entered the medical insurance but reduced its price by 80% expressed the angry message “without such a bargaining price”; Representatives of pharmaceutical companies that can enter the market, black face and appear in the field, tears in their eyes.
Comprehensive on-site news, The most embarrassing price reduction should be Chinese medicine injection. The policy trend of this year has changed. The provincial medical insurance catalogue has no additional authority. In the self-funded market, there is no competitive drug company that relies on the health insurance market in various places. No matter how much the price is to be lowered, Live the only opportunity to enter the national health insurance, and the huge price is that the profit is no longer impressive.
Multiple sources claim that all four PD-1 inhibitors have been negotiated successfully
Combining news from multiple sources, the four most concerned PD-1 inhibitor medical insurance negotiations have been successful, but have not been confirmed by official channels.
The list of PD-1 inhibitors entering the medical insurance negotiating list includes BMS’s Navulitis monoclonal antibody (commonly known as O medicine), Merck Pabolizumab (commonly known as K medicine), Junshi Bio’s Treipril monoclonal antibody and Cinda’s Cindy single anti.
These four varieties were approved for listing before December 31, 2018, and they seized the opportunity to enter the medical insurance. External evaluation, “No matter how the medical insurance bureau bids, Cinda Bio and Junshi Biology must harden their scalp into medical insurance.” At present, Hengrui PD-1 has also been listed, but the time to market is relatively late, and this negotiation is not available.
At present, B medicine’s O medicine is 9250 yuan / branch (Specification: 100mg/10ml), Merck’s K medicine is 17918 yuan / support < Span class="text-remarks" laBel="Remarks"> (Specifications: 100mg/4ml), Junshi Bio’s Treipril monoclonal antibody is 7200 yuan / branch (240mg /6ml), Cinda’s Syndimumab is 7838 yuan / (100mg/10ml).
For patients of conventional weight, O medicine is about 440,000 a year, K medicine is about 600,000 a year, Treriply monoclonal antibody is about 187,200 a year, and Dililimumab is about 167,000 a year. In addition, the four drugs have different drug policy, so the final cost will be different.
For the high-priced PD-1 to be included in medical insurance, a share of the medical insurance fund, the industry has been arguing for a long time. Eight points in the interview found that the relevant experts close to medical insurance are not worried about this. The most important issue is that the medical insurance catalogue is only reimbursed according to the scope of the indications, and this negotiation will strictly limit the indications and a certain line of treatment.
In 2018, O medicine approved for indication is metastatic non-small cell lung cancer (NSCLC) second-line treatment for adult patients, K medicine is In the second-line melanoma, Treipril monoclonal antibody is a second-line melanoma, and the Syndilumab is a relapsed/refractory classic Hodgkin’s lymphoma.
Despite the high price, PD-1 sales are very good. In the first nine months of 2019, global sales of K and O drugs were nearly $8 billion and $5.441 billion, respectively. It is estimated that by 2025, K medicine sales will reach 22.5 billion US dollars, and O medicine will be 12 billion US dollars.
In China, K medicine has sold more than 2 billion yuan in one year after the first prescription was issued on September 20, 2018. The two domestically-produced drugs, Cinda’s Sindhi monoclonal antibody and Junshi Bio’s Treipril monoclonal antibody, also achieved sales of 346 million yuan and 308 million yuan in the first half of this year.
Compared with past oncology drugs, PD-1 inhibitors have better efficacy and fewer side effects. Entering medical insurance can make more patients more affordable and affordable.
Is the medical insurance plate enough?
The medical insurance plate is so bigIf so many medicines are in the medical insurance directory, is it really enough?
The 17 anti-tumor varieties successfully negotiated in 2018 have spent 6 billion yuan on one-year medical insurance fund expenditure.
And eight points of health news alone learned that the medical insurance bureau has allocated about 15 billion medical insurance fund budgets for all negotiating varieties, and according to experts, the 150 varieties need more than 100 billion yuan, but in fact, according to the final With 15 billion plates, “the price will hit the price of the ankle.” Of course, because this is a competitive negotiation, if some drugs are out, then the drugs that are imported can be allocated a little more.
Although the results have not been fully announced, according to the current price cuts and corporate response, some experts predict that the price of new drugs may be lower than the old drugs of similar products in the regular catalogue. Drug prices may be lower than DPP4, and PD-1 prices may be lower than those with indications.
According to other media reports, the representative of a listed pharmaceutical company in China yesterday participated in the negotiations, saying that the price was too low, “feeling experts wrong a decimal point.” The representative said that the company had a diabetes drug to participate in the national medical insurance negotiations in the afternoon, but the intention price given by the medical insurance bureau negotiation experts was 90% lower than the original price.
The competition in diabetes is getting hotter
The eight-point health news was learned from the negotiation site yesterday that Xi’an Janssen’s Kagley net film negotiation was successful, and the specific decline is still unknown. Cagliflozin is an important variety of Xi’an Janssen in the field of diabetes.
There are seven major classes of hypoglycemic drugs commonly used in clinical practice, including biguanides, sulfonylureas, glinides, alpha-glucosidase inhibitors, thiazolidinediones, DPP4 inhibitors, and SGLT-2 inhibitors. “Gleevec” type hypoglycemic agents are SGLT-2 inhibitors, and are hypoglycemic innovative drugs, which are highly anticipated by the market.
At present, Xi’an Janssen’s Kaglipin, AstraZeneca’s Daglipex, and Boehringer Ingelheim’s Engeljein, three new global “Gleevec” imported hypoglycemic drugs are successively in China. Listed and tried to nurture China’s 40 billion diabetes market. However, due to the recent entry into the Chinese market, the market share is not large. According to the sample hospital data, in 2017, the sales of “Gleevec” new drugs in China did not exceed 10 million yuan, but this did not affect the momentum of such drugs in the field of diabetes.
This year, all three varieties have taken the initiative to drop a round in the local recruitment.This move is considered to be preparing for the general medical insurance catalog.
Xi’an Janssen’s Caglifloz tablets fell from 15.9 yuan/piece to 9.6 yuan/piece, a drop of 40%. In the case of AstraZeneca’s Daglibene, it also fell from 22.3 yuan/piece to 15.9 yuan/piece in some provinces. At present, the lowest market price is Boehringer Ingelheim’s Engeljein, which has dropped to 9.75 yuan per piece in many provinces.
Unexpectedly, these three varieties did not appear in the August 2019 regular catalog.
According to the eight points, the above three varieties have been included in the list of negotiations. Before the negotiations, experts from the medical insurance bureau analyzed that the three varieties will only enter one big probability. “Otherwise, the price cannot be negotiated.” Because the current prices of these three varieties have actually been roughly the same as DPP4 inhibitors, DPP4 inhibitors are also new drugs for hypoglycemics.
There is controversy in the industry to include the three varieties of the same mechanism in the negotiation list. One is that the price has been greatly reduced in the market regulation, and the price of other hypoglycemic drugs is not much different; the second is the negotiation. It will waste too much administrative resources; the third is that if only one species is finally entered into medical insurance, it is more difficult to cut the price twice.
The practice of DPP4 inhibitors is that five DPP4 inhibitors of the same mechanism on the market were included in the regular Category B catalogue in 2017 when the country adjusted the health care catalogue. Since then, these drugs have formed a competitive situation in the process of bidding in various provinces, and actively cut prices. Before entering the medical insurance catalogue, the prices of these five DPP4 inhibitors in the provinces were about 11 yuan, and they fell to about 8 yuan after entering the medical insurance catalogue.
This article is from WeChat public account:Eight Health (sight:HealthInsight)